Poster session

[P1-3-37] Improvement effect of midazolam on bone loss

〇HIROKO HARIGAYA^1,2, TAKEO KARAKIDA², RYUUJI YAMAMOTO², RISAKO CHIBA-OHKUMA², HIROSHI KAWAHARA¹, YASUO YAMAKOSHI² (1. Dept Dent Anesthesiol, Tsurumi Univ Sch Dent Med, 2. Dept Biochem Mo Biol, Tsurumi Univ Sch Dent Med)

Keywords:ミダゾラム、骨吸収、破骨細胞

Midazolam (MDZ) is a benzodiazepine anesthetic commonly used for intravenous sedation. Our objective: is to investigate the effect of MDZ on osteoclasts in bone resorption. Methods: RANKL and MDZ were added to mouse-derived macrophage-like cells (RAW264 cells), and the activity of tartaric acid resistant acid phosphatase (TRAP) was measured on 3rd day of culture. In addition, the cells were cultured in a calcium phosphate-coated culture plate for 4 days and the bone resorption ability was examined. ICR mice were used for animal experiments. Lipopolysaccharide (LPS) and MDZ were administered to the parietal region of mice to evaluate the effect of MDZ on LPS-induced inflammatory bone destruction. MDZ alone was administered every 2 days and the parietal bone was removed after 7 days. Results: In culture experiments using RAW264 cells, MDZ suppressed osteoclastic differentiation and bone resorption capacity in a concentration-dependent manner. 3D micro-CT imaging showed that the rate of bone resorption tended to decrease in MDZ compared to LPS alone. A comparison of the volume in the skull showed a slight increasing tendency in the MDZ compared to the LPS. Discussion: MDZ has been shown to inhibit osteoclastic differentiation and bone resorption, suggesting that it has a facilitating effect on increasing bone mass.